Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation

British Journal of Pharmacology

Volumn 169, Issue 6, 2013, Pages 1404-1416

  Koh, Eun Ji ^a   Yoon, Seong Jin ^a   Lee, Sun Mee ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

ischaemia reperfusion; liver; losartan; PPAR ; RAGE

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALANINE AMINOTRANSFERASE; CASPASE 3; CYTOCHROME C; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOSARTAN; MACROPHAGE INFLAMMATORY PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN C JUN; RAGE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GENE OVEREXPRESSION; LIVER INJURY; LIVER ISCHEMIA; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; ANIMALS; APOPTOSIS; CELL NUCLEUS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; LIVER; LOSARTAN; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; PPAR GAMMA; PROTECTIVE AGENTS; PROTEIN TRANSPORT; RANDOM ALLOCATION; RECEPTORS, IMMUNOLOGIC; REPERFUSION INJURY;

EID: 84879372858     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12229     Document Type: Article

References (44)

1. Abdelrahman M, Sivarajah A, Thiemermann C, (2005). Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65: 772-781.
2. Akahori T, Sho M, Hamada K, Suzaki Y, Kuzumoto Y, Nomi T, et al. (2007). Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. J Hepatol 47: 784-792.
3. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Amano Y, Yamaguchi T, Ohno K, Niimi T, Orita M, Sakashita H, et al. (2012). Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens Res 35: 715-719.
5. An J, Nakajima T, Kuba K, Kimura A, (2010). Losartan inhibits LPS-induced inflammatory signaling through a PPAR gamma-dependent mechanism in human THP-1 macrophages. Hypertens Res 33: 831-835.
6. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR, (2000). The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 275: 16390-16399.
7. Bonde MM, Olsen KB, Erikstrup N, Speerschneider T, Lyngso C, Haunso S, et al. (2011). The angiotensin II type 1 receptor antagonist losartan binds and activates bradykinin B2 receptor signaling. Regul Pept 167: 21-25.
8. Bradham CA, Stachlewitz RF, Gao W, Qian T, Jayadev S, Jenkins G, et al. (1997). Reperfusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology 25: 1128-1135.
9. Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, et al. (2008). RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57: 1941-1951.
10. Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA, (1997). Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 26: 1513-1520.
11. Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, et al. (2008). Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res 102: 905-913.
12. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, et al. (2006). Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530: 70-80.
13. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM, (2000). Serine/threonine protein kinases and apoptosis. Exp Cell Res 256: 34-41.
14. Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, Nakashima A, et al. (2007). Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. Transplantation 84: 207-213.
15. Fondevila C, Busuttil RW, Kupiec-Weglinski JW, (2003). Hepatic ischemia/reperfusion injury-a fresh look. Exp Mol Pathol 74: 86-93.
16. Goyal SN, Bharti S, Bhatia J, Nag TC, Ray R, Arya DS, (2011). Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes Metab 13: 533-541.
17. Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, Arteel GE, (2004). Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 40: 583-589.
18. Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, et al. (2006). Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 10: 349-360.
19. Horiuchi M, Mogi M, (2011). Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol 163: 1122-1130.
20. Hyogo H, Yamagishi S, (2008). Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 14: 969-972.
21. Irving EA, Bamford M, (2002). Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab 22: 631-647.
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
23. Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R, et al. (2008). Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology 47: 215-224.
24. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, et al. (2004). Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53: 2662-2668.
26. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, et al. (2007). Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35: 482-489.
27. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, et al. (2001). Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120: 460-469.
28. Padrissa-Altes S, Franco-Gou R, Boillot O, Serafin A, Rimola A, Arroyo V, et al. (2009). Effect of angiotensin II and bradykinin inhibition in rat reduced-size liver transplantation. Liver Transpl 15: 313-320.
29. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM, (2012). Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-gamma activation in human monocytes. J Hypertens 30: 87-96.
30. Ramalho FS, Alfany-Fernandez I, Casillas-Ramirez A, Massip-Salcedo M, Serafin A, Rimola A, et al. (2009). Are angiotensin II receptor antagonists useful strategies in steatotic and nonsteatotic livers in conditions of partial hepatectomy under ischemia-reperfusion? J Pharmacol Exp Ther 329: 130-140.
31. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. (1999). PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617.
32. Schmidt AM, Yan SD, Yan SF, Stern DM, (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955.
33. Schupp M, Janke J, Clasen R, Unger T, Kintscher U, (2004). Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057.
34. Shin T, Kuboki S, Huber N, Eismann T, Galloway E, Schuster R, et al. (2008). Activation of peroxisome proliferator-activated receptor-gamma during hepatic ischemia is age-dependent. J Surg Res 147: 200-205.
35. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J, (2003). Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900.
36. Tang SC, Leung JC, Chan LY, Tsang AW, Lai KN, (2006). Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol 17: 1633-1643.
37. Tontonoz P, Spiegelman BM, (2008). Fat and beyond: the diverse biology of PPAR gamma. Annu Rev Biochem 77: 289-312.
38. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, et al. (2006). Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317: 37-43.
39. Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, et al. (2009). Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119: 1124-1134.
40. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, et al. (2000). Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 6: 1355-1361.
41. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al. (2004). Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39: 422-432.
42. Zeng S, Dun H, Ippagunta N, Rosario R, Zhang QY, Lefkowitch J, et al. (2009). Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. J Hepatol 50: 929-936.
43. Zhang TL, Fu JL, Geng Z, Yang JJ, Sun XJ, (2012). The neuroprotective effect of losartan through inhibiting AT1/ASK1/MKK4/JNK3 pathway following cerebral I/R in rat hippocampal CA1 region. CNS Neurosci Ther 18: 981-987.
44. Zhu WW, Liu XP, Wu N, Zhao TT, Zhao Y, Zhang J, et al. (2007). Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats. Mol Cell Biochem 304: 35-43.